New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation led a $175m funding round in Tune Therapeutics.

New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation led a $175m funding round in Tune Therapeutics, an epigenome editing company. The funding will accelerate the development of the company’s existing pipeline, currently anchored by Tune-401 – its clinical-stage epigenetic silencing drug for chronic Hepatitis B (HBV). It will also support the development of additional gene, cell, and regenerative therapy programs already underway at Tune, and to progress its broader mission of bringing the power and versatility of epigenetic therapies to bear on common and chronic diseases.